Study of stem cell marker nestin and its correlation with vascular endothelial growth factor and microvascular density in ependymomas
- 13 November 2013
- journal article
- research article
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 40 (6) , 714-725
Abstract
Background Ependymomas are relatively rare glial tumours, whose pathogenesis is not well elucidated. They are enigmatic tumours that show site‐specific differences in their biological behaviour. Recent studies have hypothesized that ependymoma cancer stem cells (CSCs) are derived from radial glia and express stem cell markers such as nestin, which is associated with a poor prognosis. CSCs reside in ‘vascular niches’, where endothelial cells and molecular signals like vascular endothelial growth factor (VEGF) play an important role in their survival. Studies analysing VEGF expression in ependymomas showed that ependymal vascular proliferation is less sensitive to induction by VEGF, questioning the possible beneficial effect of anti‐VEGF therapy in ependymomas. We aimed to study nestin and VEGF immunoexpression in ependymomas, correlate them with clinicopathological parameters and reveal a role for VEGF in ependymomas that extends beyond the context of tumour angiogenesis. Methods We analysed 126 cases of ependymomas of different grades and locations for nestin and VEGF immunoexpression. Endothelial cells were labelled with CD34. Vascular patterns and microvascular density was determined. Results Nestin and VEGF expression in tumour cells were more frequent in supratentorial tumours [89% (33/37) and 65% (24/37) respectively], and were associated with a significantly poor progression‐free survival (PFS). VEGF expression did not reveal any correlation with necrosis or bizarre vascular patterns. Conclusions Supratentorial location is an independent predictor of a poor PFS. Significant coexpression of nestin and VEGF suggests that latter possibly augments stem cell survival. Thus, anti‐VEGF therapy may be a good option in future for nestin immunopositive ependymomas.Keywords
This publication has 55 references indexed in Scilit:
- Nestin Expression Identifies Ependymoma Patients with Poor OutcomeBrain Pathology, 2012
- Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohortsJournal of Negative Results in BioMedicine, 2011
- Nestin in gastrointestinal and other cancers: Effects on cells and tumor angiogenesisWorld Journal of Gastroenterology, 2011
- Pediatric brain tumor cancer stem cells: cell cycle dynamics, DNA repair, and etoposide extrusionNeuro-Oncology, 2010
- Cross-species genomics matches driver mutations and cell compartments to model ependymomaNature, 2010
- Relapsed intracranial ependymoma in children in the UK: Patterns of relapse, survival and therapeutic outcomeEuropean Journal of Cancer, 2009
- Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patientsJournal of Experimental & Clinical Cancer Research, 2008
- Stem Cell Marker CD133 Affects Clinical Outcome in Glioma PatientsClinical Cancer Research, 2008
- Nestin expression ? a property of multi-lineage progenitor cells?Cellular and Molecular Life Sciences, 2004
- The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical eraCancer, 2004